{
    "Clinical Trial ID": "NCT00749931",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Standard of Care (SOC)",
        "  Standard of Care arm - standard of care lumpectomy procedure",
        "  Lumpectomy: Standard of care lumpectomy procedure",
        "INTERVENTION 2: ",
        "  Device + (Standard of Care) SOC",
        "  Use of the device in addition to the standard of care lumpectomy procedure.",
        "  MarginProbe: Device use to assess margin status of the excised specimen surface.",
        "  Lumpectomy: Standard of care lumpectomy procedure"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Women histologically diagnosed with carcinoma of the breast",
        "  Women with non-palpable malignant lesions, requiring image guided localization.",
        "  Undergoing lumpectomy (partial mastectomy) procedure.",
        "  Age 18 years or more",
        "  Signed ICF",
        "Exclusion Criteria:",
        "  Multicentric disease (histologically diagnosed cancer in two different quadrants of the breast)",
        "  Bilateral disease (diagnosed cancer in both breasts)",
        "  Neoadjuvant systemic therapy",
        "  Previous radiation in the operated breast",
        "  Prior surgical procedure in the same breast",
        "  Implants in the operated breast",
        "  Pregnancy",
        "  Lactation",
        "  Participating in any other investigational study for either drug or device which can influence collection of valid data under this study."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  The Primary Effectiveness Endpoint is a Measure of Intraoperative Success in Addressing Positive Margins as Detected by Permanent Pathology)by Additional Oriented Tissue Re-excision From the Surgical Cavity.",
        "  Tests the efficacy of the device to intra-operatively assess positive margins (superiority) - CSR is 'positive' when all positive margins, as detected by histology, on the main specimen addressed intra-operatively",
        "  Time frame: two weeks after surgery",
        "Results 1: ",
        "  Arm/Group Title: Standard of Care (SOC)",
        "  Arm/Group Description: Standard of Care arm - standard of care lumpectomy procedure",
        "  Lumpectomy: Standard of care lumpectomy procedure",
        "  Overall Number of Participants Analyzed: 147",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants analyzed  22.4",
        "Results 2: ",
        "  Arm/Group Title: Device + (Standard of Care) SOC",
        "  Arm/Group Description: Use of the device in addition to the standard of care lumpectomy procedure.",
        "  MarginProbe: Device use to assess margin status of the excised specimen surface.",
        "  Lumpectomy: Standard of care lumpectomy procedure",
        "  Overall Number of Participants Analyzed: 163",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants analyzed  71.8"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/298 (1.68%)",
        "  Infections and infestations  1/298 (0.34%)",
        "  Injury, poisoning and procedural complications  3/298 (1.01%)",
        "  Neoplasms benign, malignant and unspecified (incl cysts and polyps)  0/298 (0.00%)",
        "  Reproductive system and breast disorders  1/298 (0.34%)",
        "  Vascular disorders  0/298 (0.00%)",
        "Adverse Events 2:",
        "  Total: 6/298 (2.01%)",
        "  Infections and infestations  2/298 (0.67%)",
        "  Injury, poisoning and procedural complications  2/298 (0.67%)",
        "  Neoplasms benign, malignant and unspecified (incl cysts and polyps)  1/298 (0.34%)",
        "  Reproductive system and breast disorders  0/298 (0.00%)",
        "  Vascular disorders  1/298 (0.34%)"
    ]
}